Harvard Medical School at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Harvard Medical School takes part in 4 sessions at ASH 2026 in New Orleans. Its program spans less common blood disorders such as AL amyloidosis, systemic mastocytosis and immune thrombocytopenia, alongside CAR T for lymphoma. It also covers earlier diagnosis of AL amyloidosis and risk grouping across indolent and advanced mastocytosis.
| Organization | ASH 2026 Attendance |
|---|---|
Harvard Medical School Boston, MA | |
Harvard University's medical school in Boston, whose faculty work across affiliated hospitals including Dana-Farber, Mass General and Brigham and Women's. | Symposium Fri Dec 11 11:00am–2:00pm Actionable Approaches to AL Amyloidosis Care: Diagnosing Earlier, Treating Smarter, Managing Together Diagnosing light-chain amyloidosis earlier, personalizing treatment including fibril-targeting drugs, supporting patients, and improving team workflows. Symposium Fri Dec 11 11:00am–2:00pm CAR T-Cell Agent Integration in Lymphoma: A Masterclass for Real-World Implementation CAR-T for relapsed B-cell lymphomas, from patient selection and referral to managing immune and nerve toxicities, survivorship, and off-the-shelf products. Symposium Fri Dec 11 3:00pm–6:00pm ITP at a Crossroads: Closing Knowledge Gaps in Pathophysiology, Treatment Selection, and Patient-Centred Care Personalizing immune thrombocytopenia care beyond platelet counts, weighing new therapies alongside fatigue, cognition, heavy periods, and quality of life. Symposium Fri Dec 11 11:00am–2:00pm Mastering Systemic Mastocytosis: Diagnostic Criteria, Risk Stratification, and Patient-Centered Treatment Across Indolent and Advanced Disease Diagnosing systemic mastocytosis, separating indolent from advanced disease, preventing anaphylaxis, and choosing between symptom control and Kit-targeted drugs. |
Instantly find 20 buyers from Harvard Medical School
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction